The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Africa pushes for climate finance, adaptation action ahead of COP32
- Media credibility crucial to success of 2027 polls – GOCOP president
- NEMA distributes relief materials to Abia windstorm, erosion victims
- Radda flags off ₦1.4bn Ingawa hospital upgrade
- LAWMA targets faster waste removal in 60-day plan
- NAFDAC seizes, destroys ₦100bn worth of unsafe products
- Jigawa confirms 242 diphtheria cases across 19 LGAs
- Rotary takes free cancer screening to Plateau community
